triazolam
Adjunctive therapy • Brands: HALCION
Last reviewed: 2026-02-12
General information
- Class: Adjunctive therapy
- Common US brands: HALCION
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2026-02-12
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Short-acting benzodiazepine hypnotic; GABA-A receptor positive allosteric modulator.
Metabolism & Half‑life
- Metabolism: CYP3A4
- Half‑life: Single-dose range 1.5–5.5 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Halcion (triazolam) prescribing information — DailyMed (2026)
- Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (2017)
- ASAM guideline on benzodiazepines — Journal of Addiction Medicine (2020)
- Residual effects of medications for sleep disorders on driving performance — European Neuropsychopharmacology (2024)